Slides
Page 1
Q3 2025 Earnings Presentation © 2025 Esperion Therapeutics, Inc. All rights reserved. November 6, 2025
Page 2
© 2025 Esperion Therapeutics, Inc. All rights reserved.2 Forward-looking Statements & Disclosures This investor presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, expected profitability, future operations, commercial products, clinical development, plans for potential future product candidates, financial condition and outlook, including expected cash runway and profitability, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. Any express or implied statements contained in this investor presentation that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion’s actual results to differ significantly from those projected, including, without limitation, the net sales, profitability, and growth of Esperion’s commercial products, clinical activities and results, supply chain, commercial development and launch plans, the outcomes and anticipated benefits of legal proceedings and settlements, and the risks detailed in Esperion’s filings with the Securities and Exchange Commission. Any forward-looking statements contained in this investor presentation speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward- looking statements contained in this investor presentation, other than to the extent required by law.
Page 3
CEO Commentary © 2025 Esperion Therapeutics, Inc. All rights reserved.3 “Our third quarter performance reflects consistently strong execution across our commercial, clinical, and global expansion strategies. Recent ANDA settlements strengthen our ability to sustain market leadership, while the inclusion of bempedoic acid as a Class I, Level A recommendation in the 2025 ESC/EAS guidelines marks a pivotal milestone. We expect similar recognition in the upcoming U.S. guidelines, further solidifying bempedoic acid’s role as a foundational option in the evolving treatment paradigm.” Sheldon Koenig PRESIDENT AND CHIEF EXECUTIVE OFFICER
Page 4
Q3 2025: Delivering Consistently Strong Execution © 2025 Esperion. All Rights Reserved – Do not copy or distribute.4 Q3 TOTAL REVENUE $40.7M +31% Y/Y growth Q3 U.S. NET PRODUCT SALES $87.3M +69% Y/Y growth Finalized agreements with four generic manufacturers, including Dr. Reddy’s Bempedoic acid received Level 1a Recommendation in updated ESC/EAS Guidelines for Management of Dyslipidemia Retail Prescription Equivalents Q/Q +9%
Page 5
Outpacing the Broader Lipid-Lowering Market Delivering growth that exceeded all other non-statin therapies, including branded competitors 5 • Welcoming John Harlow as Chief Commercial Officer to drive the next phase of commercial growth and execution. • Effective November 17, 2025. Leadership Expansion • Combined progress in marketing and access drove a 9% increase in total retail prescription equivalents and a 7% increase in prescribers versus Q2 2025. • Total prescriber base now exceeds 30,000 HCPs. Commercial Performance • Launched “Can’t take a statin? Make NEXLIZET happen!” campaign, targeting statin-intolerant patients. • Quantitative data show strong HCP perception gains and conversion from awareness to use. Brand Momentum • ~50% of individuals who begin statin therapy either discontinue treatment or had over a 6-month gap in therapy within two years – representing a significant opportunity for NEXLETOL and NEXLIZET. Market Opportunity © 2025 Esperion. All Rights Reserved – Do not copy or distribute.
Page 6
• Connected-TV ads launched September 22 on Hulu and Disney+, featuring award- winning “Lipid Lurkers.” • Expanded branded commercials during Grey’s Anatomy starting October 10 to spotlight statin intolerance and position NEXLETOL and NEXLIZET as compelling alternatives. • Campaign expected to deliver ~18 million impressions, targeting adults 50+ with prior statin use, >6 million achieved as of mid- October • Achieved 87% Medicare and 86% commercial approval rates, with average $29/$36 copays for a 30-day supply. • Reflects growing payer confidence and improved access for patients. • Reinforces that getting NEXLETOL and NEXLIZET has never been easier. Access Expansion • Continued investment in targeted digital marketing and access initiatives to expand reach and drive sustained growth in 2026. • Confident these programs will continue to fuel category-leading performance across the bempedoic acid franchise. Consumer Awareness & Engagement Momentum & Outlook 6 Strengthening Patient Reach and Market Access Driving awareness through innovative digital campaigns and broadening reimbursement coverage >80% Commercial lives insuredMedicare lives insured >90% © 2025 Esperion. All Rights Reserved – Do not copy or distribute.
Page 7
Bempedoic Acid Received 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias © 2025 Esperion Therapeutics, Inc. All rights reserved.7 • Bempedoic acid was the only new non-statin included with LDL-C and CV risk reduction data. • First time a guideline has given a Level IA to recommend combination therapy based on magnitude of LDL-C reduction needed. Strike early, strike strong Recommendations Class Level Non-statin therapies with proven cardiovascular benefit (including bempedoic acid), taken alone or in combination, are recommended for patients who are unable to take statin therapy to lower LDL-C levels and reduce the risk of CV events. The choice should be based on the magnitude of additional LDL-C lowering needed. I A Bempedoic acid is recommended in patients who are unable to take statin therapy to achieve the LDL-C goal. I B The addition of bempedoic acid to the maximally tolerated dose of statin with or without ezetimibe should be considered in patients at high or very high risk in order to achieve the LDL-C goal. IIa C European Guidelines Expected to Inform Upcoming U.S. Cholesterol Treatment Guidelines
Page 8
Strategic Partnerships Driving Global Reach © 2025 Esperion Therapeutics, Inc. All rights reserved.8 Partner Daiichi Sankyo Europe Asia & South America Daiichi Sankyo Co., Ltd.Otsuka Pharmaceutical Co., Ltd. Agreement Terms Neopharm Israel HLS Therapeutics Tiered royalties and additional sales milestones • Expect approval and National Health Insurance pricing in the second half of 2025 Europe Maximizing Global Reach Across Key Regions Japan Tiered royalties, regulatory, pricing and additional sales milestones Tiered royalties and additional sales milestones • Launched in many key markets including Germany, UK, Austria, Belgium, Switzerland, Italy, Spain, Netherlands, Slovakia and Czech Republic to date • Expanded label approved in EU and UK in May/June ’24 Highlights • Received regulatory approval to market product (mono & dual) and launched: • Hong Kong in 2023 • Thailand and Macau in 2024 Israel Canada Tiered royalties and additional milestones • Filed NDA for marketing approval in Q1 2025; approval anticipated in the first half of 2026 • Expect market approval in Q4 2025 Upfront Payment, Milestones and Tiered Royalties 40 Approved in countries globally A p p r o v a l a n d l a u n c h i n a d d i t i o n a l t e r r i t o r i e s a n t i c i p a t e d i n 2 0 2 5 Australia & New Zealand CSL Seqirus Upfront and near- term milestone payments • Filed marketing application in Australia in July 2025 • Expect market approval in Q4 2026
Page 9
International Growth Continues at Strong Pace © 2025 Esperion Therapeutics, Inc. All rights reserved.9 Note: Numbers are approximate and based on an internal calculation methodology and includes Germany, UK, Austria, Belgium, Switzerland, Italy, Ireland, Spain, the Netherlands. ~600,000 patients through August 2025 - 100,000 200,000 300,000 400,000 500,000 600,000 700,000
Page 10
Pipeline Advancement
Page 11
Renal Diseases To Be Announced Primary Sclerosing Cholangitis (PSC) IND: 2026 PRODUCT/PROGRAM EXPLORATORY LEAD ID LEAD OPTIMIZATION PRECLINICAL DEVELOPMENT CLINICAL DEVELOPMENT APPROVED / COMMERCIAL MILESTONES Proven Science, Innovative Pipeline © 2025 Esperion Therapeutics, Inc. All rights reserved.11 I n n o v a t i v e P o r t f o l i o & P i p e l i n e NEXLETOL® bempedoic acid Approved 2020 Expanded label 2024 NEXLIZET® bempedoic acid and ezetimibe Approved 2020 Expanded label 2024 Triple Combination A bempedoic acid, ezetimibe, and atorvastatin NDA: 2027 Triple Combination B bempedoic acid, ezetimibe, and rosuvastatin NDA: 2027 Cardiovascular Disease (LDL-C lowering / CV Risk reduction) LDL-C: low-density lipoprotein cholesterol; CV: cardiovascular; NDA: New Drug Application; IND: Investigational New Drug Liver Diseases
Page 12
PSC: High Unmet Need Driving Significant Market Opportunity © 2025 Esperion Therapeutics, Inc. All rights reserved.12 2024 Diagnosed Prevalence of PSC US EU Annual Market Opportunity Estimate • No approved therapies with proven efficacy to cure or halt PSC progression • Potential Orphan Drug Designation & Fast Track Approval • Discovery program is internally developed and wholly-owned globally PSC: A Rare and Progressive Liver Disease 30K3-5 >$1B 46K1-2 ~76K PSC: primary sclerosing cholangitis This program highlights the broader potential of ACLY biology Selected ESP-2001 as preclinical development candidate; IND-enabling studies underway to support a planned 2026 IND filing
Page 13
Financial Update Ben Halladay, Chief Financial Officer
Page 14
Consistently Strong Third Quarter 14 © 2025 Esperion Therapeutics, Inc. All rights reserved. TOTAL REVENUE $40.7M 31% increase Y/Y U.S. NET PRODUCT SALES $87.3M 69% increase Y/Y $46.7M 128% increase Y/Y COLLABORATION REVENUE Closed on a $75 million follow-on equity offering, which provided net proceeds of approximately $72.6 million.
Page 15
Cash and 2025 Guidance 15 Cash & Cash Equivalents $92.4M Key Financial Data FY 2025 R&D Guidance FY 2025 SG&A Guidance FY 2025 OpEx Guidance1 1. Includes ~$15 million of non-cash stock-based compensation expense $55 – 65 M $160 – 170 M $215 – 235 M © 2025 Esperion Therapeutics, Inc. All rights reserved.
Page 16
Strong Prescription Trend and Increasing Physician Adoption Continue to Drive Durable Revenue Growth © 2025 Esperion Therapeutics, Inc. All rights reserved. 16 Quarterly Franchise Retail Prescription Equivalents (RPE) Trend Weekly Franchise RPE Trend1 1. Through September 26, 2025. - 20,000 40,000 60,000 80,000 100,000 120,000 140,000 160,000 180,000 200,000 220,000 240,000 260,000 280,000 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 +9% - 2,000 4,000 6,000 8,000 10,000 12,000 14,000 16,000 18,000 20,000 1/6/23 1/6/24 1/6/25
Page 17
Important Safety Information
Page 18
NEXLETOL® (bempedoic acid) Important Safety Information © 2025 Esperion Therapeutics, Inc. All rights reserved.18 • NEXLETOL is contraindicated in patients with a prior serious hypersensitivity reaction to bempedoic acid or any of the excipients. Serious hypersensitivity reactions, such as angioedema, have occurred. • Hyperuricemia: NEXLETOL may increase blood uric acid levels, which may lead to gout. Hyperuricemia may occur early in treatment and persist throughout treatment, returning to baseline following discontinuation of treatment. Assess uric acid levels periodically as clinically indicated. Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate. • Tendon Rupture: NEXLETOL is associated with an increased risk of tendon rupture or injury. Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. Discontinue NEXLETOL at the first sign of tendon rupture. Consider alternative therapy in patients who have a history of tendon disorders or tendon rupture. • The most common adverse reactions in the primary hyperlipidemia trials of NEXLETOL in ≥2% of patients and greater than placebo were upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes. • The most common adverse reactions in the cardiovascular outcomes trial for NEXLETOL at an incidence of ≥2% and 0.5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis. • Discontinue NEXLETOL when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus. Because of the potential for serious adverse reactions in a breast-fed infant, breastfeeding is not recommended during treatment with NEXLETOL. • Report pregnancies to Esperion Therapeutics, Inc. Adverse Event reporting line at 1-833-377-7633. See full prescribing information here.
Page 19
NEXLIZET® (bempedoic acid and ezetimibe) Important Safety Information © 2025 Esperion Therapeutics, Inc. All rights reserved.19 • NEXLIZET is contraindicated in patients with a prior hypersensitivity to ezetimibe or bempedoic acid or any of the excipients. Serious hypersensitivity reactions, such as anaphylaxis, angioedema, rash, and urticaria have been reported with ezetimibe or bempedoic acid. • Hyperuricemia: Bempedoic acid, a component of NEXLIZET, may increase blood uric acid levels, which may lead to gout. Hyperuricemia may occur early in treatment and persist throughout treatment, returning to baseline following discontinuation of treatment. Assess uric acid levels periodically as clinically indicated. Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate. • Tendon Rupture: Bempedoic acid, a component of NEXLIZET, is associated with an increased risk of tendon rupture or injury. Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. Discontinue NEXLIZET at the first sign of tendon rupture. Consider alternative therapy in patients who have a history of tendon disorders or tendon rupture. • The most common adverse reactions in the primary hyperlipidemia trials of bempedoic acid (a component of NEXLIZET) in ≥2% of patients and greater than placebo were upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes. • Adverse reactions reported in ≥2% of patients treated with ezetimibe (a component of NEXLIZET) and at an incidence greater than placebo in clinical trials were upper respiratory tract infection, diarrhea, arthralgia, sinusitis, pain in extremity, fatigue, and influenza. • In the primary hyperlipidemia trials of NEXLIZET, the most commonly reported adverse reactions (incidence ≥3% and greater than placebo) observed with NEXLIZET, but not observed in clinical trials of bempedoic acid or ezetimibe, were urinary tract infection, nasopharyngitis, and constipation. • The most common adverse reactions in the cardiovascular outcomes trial of bempedoic acid (a component of NEXLIZET) at an incidence of ≥2% and 0.5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis. • Discontinue NEXLIZET when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus. Because of the potential for serious adverse reactions in a breast-fed infant, breastfeeding is not recommended during treatment with NEXLIZET. • Report pregnancies to Esperion Therapeutics, Inc. Adverse Event reporting line at 1-833-377-7633. See full prescribing information here.